Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer
Nuklearmedizin - NuclearMedicine · 01.06.2026 · 65 (03) · 207-216
DOI: 10.1055/a-2825-4883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2026. Verfasst von Mehmet Tarık Tatoğlu und 6 weiteren Autor:innen. Beteiligte Einrichtung: TC Saglik Bakanligi Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Nuclear Medicine, Türkiye, Istanbul. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Neoadjuvant Therapy, Breast Neoplasms.
Abstract (Originalsprache)
Aim
Predicting axillary pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) may enable risk-adapted axillary management in clinically node-positive breast cancer (BC), but practical baseline PET-derived predictors are limited.
Methods
Single-center retrospective cohort of consecutive cN+, M0 patients with baseline [18F]FDG PET/CT–reported axillary nodal metastasis treated with NST and surgery (complete-case n=115). Axillary pCR was defined as no residual invasive carcinoma in axillary lymph nodes; isolated tumor cells and/or micrometastases were classified as non-pCR. Two prespecified ridge-penalized logistic models combined routine clinical variables with baseline PET-defined axillary burden as (i) hypermetabolic ALN count (Model A) or (ii) limited (1–3) versus advanced (≥4) burden group (Model B). Stratified 5-fold cross-validation generated out-of-fold (OOF) predictions; AUC, Brier score, and logistic recalibration slope/intercept were bootstrapped on OOF predictions (2000 resamples).
Results
Axillary pCR occurred in 59/115 (51.3%). Discrimination was good: AUC 0.80 (95% CI 0.72–0.88) for Model A and 0.79 (95% CI 0.71–0.87) for Model B. Calibration was acceptable (bootstrap-mean slope/intercept ≈1.10/0.04 and 1.08/0.03, respectively). Greater baseline PET-defined axillary extent was associated with lower odds of pCR; molecular subtype and neoadjuvant anti-HER2 therapy remained strongly associated with response.
Conclusion
Prespecified ridge models combining routine clinical variables with baseline [18F]FDG PET/CT–defined axillary burden showed good internal performance for predicting axillary pCR. External validation is required before response-adapted clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- TC Saglik Bakanligi Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Nuclear Medicine, Türkiye, Istanbul.
- TC Sağlık Bakanlığı Göztepe Prof Dr Süleyman Yalçın Şehir Hastanesi, Department of Medical Oncology, Türkiye, Istanbul.
- Göztepe Prof Dr Süleyman Yalçın Şehir Hastanesi, Nuclear Medicine, Türkiye, Istanbul.
- TC Sağlık Bakanlığı Göztepe Prof Dr Süleyman Yalçın Şehir Hastanesi, Department of Pathology, Türkiye, Istanbul.
- İstanbul Medeniyet Üniversitesi Tip Fakültesi, Department of Pathology, Türkiye, Istanbul.
- Istanbul University Faculty of Economics, Department of Econometrics, Türkiye, Istanbul.
ORCID-Profile: Mehmet Tarık Tatoğlu
Zitieren
APA
Tatoğlu, M. T., Ökten, İ. N., Ibisoglu, E., Söylemez Akkurt, T., Yerdelen Tatoğlu, F., Uslu, H., & Baysal, H. (2026). Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer. Nuklearmedizin - NuclearMedicine, 65(03), 207-216. https://doi.org/10.1055/a-2825-4883
Vancouver
Tatoğlu MT, Ökten İN, Ibisoglu E, Söylemez Akkurt T, Yerdelen Tatoğlu F, Uslu H, et al. Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer. Nuklearmedizin - NuclearMedicine. 2026;65(03):207-216. doi:10.1055/a-2825-4883
BibTeX
@article{Tatolu2026,
author = {Tatoğlu, Mehmet Tarık and Ökten, İlker Nihat and Ibisoglu, Ebru and Söylemez Akkurt, Tuçe and Yerdelen Tatoğlu, Ferda and Uslu, Hatice and Baysal, Hakan},
title = {Baseline FDG PET/CT–Defined Axillary Burden Predicts Axillary Pathologic Complete Response After Neoadjuvant Therapy in Breast Cancer},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2026},
volume = {65},
number = {03},
pages = {207--216},
doi = {10.1055/a-2825-4883}
}
EUVIMED